Heparin modulation of human plasma kallikrein on different substrates and inhibitors

Biological Chemistry

Volumn 387, Issue 8, 2006, Pages 1129-1138

  Gozzo, Andrezza J ^a   Nunes, Viviane A ^a   Cruz Silva, Ilana ^a   Carmona, Adriana K ^a   Nader, Helena B ^a   Faljoni Alario, Adelaide ^b   Sampaio, Misako U ^a   Araújo, Mariana S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antithrombin; C1 inhibitor; Factor XII; Glycosaminoglycans; Plasminogen; Synthetic substrates

Indexed keywords

ACETYLPHENYLALANYLARGINYL 4 NITROANILIDE; BLOOD CLOTTING FACTOR 12; DEXTRO PROLYLPHENYLALANYLARGINYL 4 NITROANILIDE; GLYCOSAMINOGLYCAN; GLYCYLPHENYLALANYLSERYLPROLYLPHENYLALANYLARGINYLSERYLSERYLARGINYLGLUTAMINYL N (2,4 DINITROPHENYL)ETHYLENEDIAMINE; HEPARIN; PLASMA KALLIKREIN; PLASMINOGEN; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CIRCULAR DICHROISM; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FIBRINOLYSIS; HUMAN; HYDROLYSIS; KALLIKREIN KININ SYSTEM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ALPHA 1-ANTITRYPSIN; ANTITHROMBINS; CATALYSIS; COMPLEMENT C1 INHIBITOR PROTEIN; ENZYME INHIBITORS; FACTOR XII; HEPARIN; HUMANS; HYDROLYSIS; PEPTIDES; PLASMA KALLIKREIN; PLASMINOGEN; PROTEIN STRUCTURE, SECONDARY; TIME FACTORS;

EID: 33746878880     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.139     Document Type: Article

References (69)

1. Almeida, P.C., Nantes, I.L., Chagas, J.R., Rizzi, C.C., Faljoni-Alario, A., Carmona, E., Juliano, L., Nader, H.B., and Tersariol, I.L. (2001). Cathepsin B activity regulation. Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation. J. Biol. Chem. 276, 944-951.
2. Araújo-Viel, M.S., Grisolia, D., Juliano, M.A., and Prado, E.S. (1983). Di- and tripeptidyl-p-nitroanilides as substrates for glandular and plasma kallikreins. Arq. Biol. Tecnol. 26, 287-287.
3. Asakai, R., Davie, E.W., and Chung, D.W. (1987). Organization of the gene for human factor XI. Biochemistry 26, 7221-7228.
4. Beatty, K., Robertie, P., Senior, R.M., and Travis, J. (1980). Determination of oxidized α-1-proteinase inhibitor in serum. J. Lab. Clin. Med. 100, 186-192.
5. Bernfield, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., and Zako, M. (1999). Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777.
6. Bhoola, K.D., Elson, C.J., and Dieppe, P.A. (1992). Kinins - key mediators in inflammatory arthritis? Br. J. Rheumatol. 31, 509-518.
7. Bode, W., Chen, K., Bartels, K., Kutzbach, C., Schmidt-Kastner, G., and Bartunik, H. (1983). Refined 2 Å X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase: crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J. Mol. Biol. 164, 237-282.
8. Bohm, G., Muhr, R., and Jaenicke, R. (1992). Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 5, 191-195.
9. Brunnee, T., Reddigari, S.R., Shibayama, Y., Kaplan, A.P., and Silverberg, M. (1997). Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin. Exp. Allergy 27, 653-663.
10. Cardin, A.D. and Weinstraub, H.J. (1989). Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32.
11. Cardin, A.D., Demeter, D.A., Weintraub, H.J., and Jackson, R.L. (1991). Molecular design and modeling of protein-heparin interactions. Methods Enzymol. 203, 556-583.
12. Chung, D.W., Fujikawa, K., McMullen, B.A., and Davie, E.W. (1986). Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25, 2410-2417.
13. Collen, D. and Lijnen, H.R. (1991). Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78, 3114-3124.
14. Davie, E.W. and Ratnoff, O.D. (1964). Waterfall sequence for intrinsic blood clotting. Science 145, 1310-1312.
15. Gan, Z.R., Li, Y., Chen, Z., Lewis, S.D., and Shafer, J.A. (1994). Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J. Biol. Chem. 269, 1301-1305.
16. Gozzo, A.J., Nunes, V.A., Carmona, A.K., Nader, H.B., von Dietrich, C.P., Silveira, V.L., Shimamoto, K., Ura, N., Sampaio, M.U., Sampaio, C.A., and Araújo, M.S. (2002). Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Int. Immunopharmacol. 2, 1861-1865.
17. Gozzo, A.J., Nunes, V.A., Nader, H.B., Dietrich, C.P., Carmona, A.K., Sampaio, M.U., Sampaio, C.A.M., and Araújo, M.S. (2003). Glycosaminoglycans affect the interaction of human plasma kallikrein with plasminogen, factor XII and inhibitors. Braz. J. Med. Biol. Res. 36, 1055-1059.
18. Gurewich, V., Johnstone, M., Loza, J.P., and Pannell, R. (1993). Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 318, 317-321.
19. Heimark, R.L. and Davie, E.W. (1981). Bovine and human plasma prekallikrein. Methods Enzymol. 80, 157-172.
20. Ho, D.H., Badellino, K., Baglia, F.A., and Walsh, P.N. (1998). A binding site for heparin in the apple 3 domain of factor XI. J. Biol. Chem. 273, 16382-16390.
21. Ho, D.H., Baglia, F.A., and Walsh, P.N. (2000). Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domain. Biochemistry 39, 316-323.
22. Hoppensteadt, D., Walenga, J.M., and Fareed, J. (1990). Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb. Res. 60, 191-200.
23. Huber, K., Kirchheimer, J., and Binder, B.R. (1982). Rapid isolation of high molecular weight urokinase from native human urine. Thromb. Haemost. 47, 197-202.
24. Ichinose, A., Fujikawa, K., and Suyama, T. (1986). The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261, 3486-3469.
25. Jackson, C.M. and Nemerson, Y. (1980). Blood coagulation. Annu. Rev. Biochem. 49, 765-811.
26. Jörg, M. and Binder, B.R. (1985). Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb. Res. 39, 323-331.
27. Kaplan, A.P. and Silverberg, M. (1987). The coagulation-kinin pathway of human plasma. Blood 70, 1-15.
28. Kaplan, A.P., Joseph, K., and Silverberg, M. (2002). Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109, 195-209.
29. Kjellen, L. and Lindahl, U. (1991). Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443-475.
30. Lin, Y., Pixley, R.A., and Colman, R.W. (2000). Kinetic analysis of the role of zinc in the interaction of domain 5 of high-molecular weight kininogen (HK) with heparin. Biochemistry 39, 5104-5110.
31. Lindahl, U., Backstrom, G., Thumberg, L., and Leder, I.G. (1980). Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc. Natl. Acad. Sci. USA 77, 6551-6558.
32. Linhardt, R.J., Al-Hakim, A., Liu, J.A., Hoppensteadt, D., Mascellani, G., Bianchini, P., and Fareed, J. (1991). Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem. Pharmacol. 42, 1609-1619.
33. Mauron, T., Lämmle, B., and Wuillemin, W.A. (1998). Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb. Haemost. 80, 82-86.
34. McCarty, M.F. (1998). Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier-implications for use of glucosamine in inflammatory disorders. Med. Hypotheses 51, 11-15.
35. McGuffin, C.J., Bryson, K., and Jones, D.T. (2000). The PSIPRED protein structure prediction server. Bioinformatics 16, 404-405.
36. Motta, G., Rojkjaer, R., Hasan, A.A.K., Cines, D.B., and Schmaier, A.H. (1998). High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91, 516-528.
37. Motta, G., Shariat-Madar, Z., Mahdi, F., Sampaio, C.A., and Schmaier, A.H. (2001). Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thromb. Haemost. 86, 840-847.
38. Nader, H.B. and Dietrich, C.P. (1989). Natural occurrence and possible biological role of heparin. In: Heparin. Chemical and Biological Properties, Clinical Application, D.A. Lane and U. Lindahl, eds. (London, UK: Edward Arnold), p. 81.
39. Nader, H.B., Dietrich, C.P., Buonassisi, V., and Colburn, P. (1987). Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Biochemistry 84, 3565-3569.
40. Nader, H.B., Lopes, C.C., Rocha, H.A., Santos, E.A., and Dietrich, C.P. (2004) Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities. Curr. Pharm. Des. 10, 951-966.
41. Nunes, V.A., Gozzo, A.J., Sampaio, M.U., Juliano, M.A., Sampaio, C.A.M., and Araújo, M.S. (2003). Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site. J. Protein Chem. 22, 533-539.
42. Olson, S.T., Sheffer, R., and Francis, A.M. (1993). High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein. Biochemistry 32, 12136-12147.
43. Oshima, G. (1989). Effects of different heparins on the enhancement of the thrombin-antithrombin reaction. Biol. Chem. Hoppe-Seyler 371, 37-42.
44. Pesquero, J.B. and Bader, M. (1998). Molecular biology of the kallikrein-kinin system: from structure to function. Braz. J. Med. Biol. Res. 31, 1197-1203.
45. Ragazzi, M., Ferro, D.R., Perly, B., Sinai, P., Petitou, M., and Choay, J. (1990). Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III. Carbohydr. Res. 195, 169-185.
46. Renné, T., Dedio, J., David, G., and Müller-Esterl, W. (2000). High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 275, 33688-33696.
47. Rennë, T., Schuh, K., and Müller-Esterl, W. (2005). Local bradykinin formation is controlled by glycosaminoglycans. J. Immunol. 175, 3377-3385.
48. Rose, M.J. and Page, C. (2004). Glycosaminoglycans and the regulation of allergic inflammation. Curr. Drug Targets Inflamm. Allergy 3, 221-225.
49. Sampaio, C.A. and Grisolia, D. (1978). Human plasma kallikrein. Preliminary studies on hydrolysis of proteins and peptides. Agents Actions 8, 125-131.
50. Santos, E.A., Rocha, L.R., Pereira, N.M., Andrade, G.P., Nader, H.B., and Dietrich, C.P. (2002). Mast cells are present in epithelial layers of different tissues of the mollusc Anomalocardia brasiliana. In situ characterization of heparin and a correlation of heparin and histamine concentration. Histochem. J. 34, 553-558.
51. Schapira, M., Scott, C.F., and Colman, R.W. (1981). Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 20, 2738-2743.
52. Schmaier, A.H. (1998). Plasma contact activation: a revised hypothesis. Biol. Res. 31, 251-262.
53. Schmaier, A.H. (2002). The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J. Clin. Invest. 109, 1007-1009.
54. Schwartz, N.B. (1992). Carbohydrate metabolism II: special pathways. In: Textbook of Biochemistry with Clinical Correlations, 3rd Ed., T.M. Devlin, ed. (New York, USA: Wiley-Liss) pp. 359-386.
55. Scott, C.F., Carrell, R.W., Glaser, C.B., Kueppers, F., Lewis, J.H., and Colman, R.W. (1986). Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J. Clin. Invest. 77, 631-634.
56. Shariat-Madar, Z., Mahdi, F., and Schmaier, A.H. (2002). Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277, 17962-17969.
57. Sheehan, J.P. and Sadler, J.E. (1994). Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. USA 91, 5518-5522.
58. Silverberg, M., Dunn, J.T., Garen, L., and Kaplan, A.P. (1980). Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J. Biol. Chem. 255, 7281-7286.
59. Soons, H., Janssen-Claessen, T., Tans, G., and Hemker, H.C. (1987). Inhibition of factor XIa by antithrombin III. Biochemistry 26, 4624-4629.
60. Takahashi, H.K., Nader, H.B., and Dietrich, C.P. (1981). A method for rapid quantitation and preparation of antithrombin III - high-affinity heparin fractions. Anal. Biochem. 116, 456-461.
61. Tankersley, D.L. and Finlayson, J.S. (1984). Kinetics of activation and autoactivation of human factor XII. Biochemistry 23, 273-279.
62. Tankersley, D.L., Alving, B.M., and Finlayson, J.S. (1983). Activation of factor XII by dextran sulfate: the basis for an assay of factor XII. Blood 62, 448-456.
63. Teien, A.N., Abildgaard, U., and Höök, M. (1976). The antico-agulant effect of heparan sulfate and dermatan sulfate. Thromb. Res. 8, 859-867.
64. Tersariol, I.L., Pimenta, D.C., Chagas, J.R., and Almeida, P.C. (2002). Proteinase activity regulation by glycosaminoglycans. Braz. J. Med. Biol. Res. 35, 135-144.
65. Tyler-Cross, R., Sobel, M., Marques, D., and Harris, R.B. (1994). Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy. Protein Sci. 3, 620-627.
66. van der Graaf, F., Koedam, J.A., and Bruma, B.N. (1983). Inactivation of kallikrein in human plasma. J. Clin. Invest. 71, 149-158.
67. Wilkinson, G.N. (1961). Statistical estimations in enzyme kinetics. Biochem. J. 80, 324-332.
68. Wuillemin, W.A., Eldering, E., Citarella, F., De Ruig, C.P., ten Cate, H. and Hack, C.E. (1996). Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271, 12913-12918.
69. Zhao, M., Abdel-Razek, T., Sun, M.F., and Gailani, D. (1998). Characterization of heparin binding site on the heavy chain of factor. XI J. Biol. Chem. 273, 31153-31159.